Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder - Bigdeli TB, Barr PB, Rajeevan N, Graham DP, Li Y, Meyers JL, Gorman BR, Peterson RE, Sayward F, Radhakrishnan K, Natarajan S, Nielsen DA, Wilkinson AV, Malhotra AK, Zhao H, Brophy M, Shi Y, O'Leary TJ, Gleason T, Przygodzki R, Pyarajan S, Muralidhar S, Gaziano JM, Huang GD, Concato J, Siever LJ, Delisi LE, Kimbrel NA, Beckham JC, Swann AC, Kosten TR, Fanous AH, Aslan M, Harvey PD.
Persons diagnosed with schizophrenia (SCZ) or bipolar I disorder (BPI) are at high risk for self-injurious behavior, suicidal ideation, and suicidal behaviors (SB). Characterizing associations between diagnosed health problems, prior pharmacological treatm... (Source: SafetyLit)
Source: SafetyLit - March 18, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
MRI May Predict Who'll Respond Best to Schizophrenia Treatment
FRIDAY, March 15, 2024 -- Specialized brain scans may accurately predict whether a psychotic patient will go on to develop treatment-resistant schizophrenia, Dutch researchers report.
The scan— called a neuromelanin-sensitive MRI, or NM-MRI... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 15, 2024 Category: General Medicine Source Type: news
Association of empathy with clinical symptoms and cognitive function in chronic schizophrenia patients with and without suicide attempts - Ma Z, Tian Y, Li J, Liu J, Wang DM, Zhang XY.
Cognitive impairment is recognized as a risk factor for suicide in schizophrenia (SZ) patients. Despite empathy being an important aspect of social cognition, the association between suicidal behavior and empathy has received little attention. We aimed to ... (Source: SafetyLit)
Source: SafetyLit - March 15, 2024 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news
LSD Anxiety Win; Pimavanserin Schizophrenia Flop; 'Bright Light' for Depression?
(MedPage Today) -- In a phase IIb study, a single dose of an investigational LSD-containing drug (MM120) led to significantly greater reductions in 12-week scores on the Hamilton Anxiety Rating Scale compared with placebo, according to Mind Medicine... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 13, 2024 Category: Psychiatry Source Type: news
Schizophrenia Tied to Increased Cardiovascular Disease Risk Schizophrenia Tied to Increased Cardiovascular Disease Risk
Schizophrenia diagnosis increases the risk for myocardial infarction, angina, and other cardiovascular diseases, especially in women.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - March 13, 2024 Category: Primary Care Tags: Psychiatry Source Type: news
Acadia Pharma ’s stock falls 15% after failed drug trial
One of Acadia Pharma’s drugs failed to meet goals of a late-stage trial about a schizophrenia treatment.#acadiapharmas (Source: Reuters: Health)
Source: Reuters: Health - March 11, 2024 Category: Consumer Health News Source Type: news
Acadia to Stop Trials Of Antipsychotic Drug After It Fails Schizophrenia Study Acadia to Stop Trials Of Antipsychotic Drug After It Fails Schizophrenia Study
Acadia Pharmaceuticals said on Monday it does not plan to conduct further clinical trials of its antipsychotic drug, pimavanserin, after it failed to improve negative...Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 11, 2024 Category: Consumer Health News Tags: Psychiatry Source Type: news
Suicide probability among patients with schizophrenia and bipolar disorder - Y üksel A, Yilmaz EB, Dikmen SNT.
PURPOSE: To evaluate the possibility of suicide and related factors among individuals with schizophrenia and bipolar disorder (BD). METHOD: Data were collected for 270 individuals registered in a community mental health center using the Suicide Pro... (Source: SafetyLit)
Source: SafetyLit - March 11, 2024 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
How service dog helps man with schizophrenia during hallucinations
A man with schizophrenia has shared footage of the moment a service dog came to his aid after he began experiencing "visual hallucinations." Schizophrenia—a mental health condition that manifests itself through hearing voices, seeing things that are not real, or having unusual beliefs and confused…#schizophrenia #johnshopkinsmedicine #kodygreen #wisconsin #luna #lunagreen (Source: Reuters: Health)
Source: Reuters: Health - March 9, 2024 Category: Consumer Health News Source Type: news
FDA Rejects Schizophrenia Drug; Psilocybin for Anxiety; Solitary Confinement Lawsuit
(MedPage Today) -- The FDA rejected the investigational drug roluperidone for the treatment of negative symptoms in patients with schizophrenia and called for at least one more positive study, according to developer Minerva Neurosciences.
Six... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 6, 2024 Category: Psychiatry Source Type: news
Systematic review and meta-analysis: rates of violence during first-episode psychosis (FEP) - Youn S, Guadagno BL, Byrne LK, Watson AE, Murrihy S, Cotton SM.
BACKGROUND: Most people with psychotic disorders will never commit an act of violence. However, the risk of violence committed by people with schizophrenia is higher than the general population. Violence risk is also known to be highest during the first ep... (Source: SafetyLit)
Source: SafetyLit - March 4, 2024 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Schizophrenia Linked to Increased Risk for Subsequent CVD Events
FRIDAY, March 1, 2024 -- Schizophrenia is associated with an increased risk of subsequent cardiovascular disease (CVD) events, with the association stronger in women, according to a study published online Feb. 27 in the Journal of the American Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 1, 2024 Category: Pharmaceuticals Source Type: news
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 27, 2024 Category: Drugs & Pharmacology Source Type: news
FDA rejects Burlington biotech ’s schizophrenia drug, sends stock tumbling
Minerva Neurosciences' schizophrenia drug has run into another roadblock on its path to approval. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 27, 2024 Category: Pharmaceuticals Authors: Hannah Green Source Type: news
Minerva Neurosciences Falls as US FDA Declines to Approve Drug for Schizophrenia Symptoms Minerva Neurosciences Falls as US FDA Declines to Approve Drug for Schizophrenia Symptoms
Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration (FDA) has declined to approve its drug to regulate behavioral changes in patients with...Reuters Health Information (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - February 27, 2024 Category: Psychiatry Tags: Psychiatry Source Type: news
